TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in markers of athero-thrombosis and inflammation (IL-1 beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in High sensitivity C-reactive protein (hsCRP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Adiponectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vertical Clinical Attachment Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tedizolid Area Under the Concentration Time-curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMasters Universities Osteoarthritis Index-WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Year Survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Pulse pressure variation (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Corrected flow time (FTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasmatic level of sCD40L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Beck Depression Inventory (BDI-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in Headache Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anti-proliferative Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic function at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival Rate at Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Survival Rate at Month 12
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) at Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) at Month 12
Endpoint domain: Mortality/survival
Primary endpoint: Duration of fever (>38°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sterilization of the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of the blood inflammatory indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of renal scarring documented at 12 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Mean Beck Depression Inventory (BDI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Subscales of Mood Survey Scale at 3 Hours
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Feeling Scale at 3 Hours
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Felt Arousal Scale at 3 Hours
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with accurate pre-operative surgical treatment planning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of SCORAD-50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sanitation-Related Psychosocial Stress Scale (SRPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HIV virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immune senescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: frailty phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain related to hip function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants free from Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hib, Poliomyelitis, PT and FHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in symptom severity of primary diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Performed a Skin Self-Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUC from time 0 to the last quantifiable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum observed plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Lab Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Examination Findings (PE Findings)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with high-risk OLGA stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-curve for drowsiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-curve for dryness of the mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to persistent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of living donor kidney transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of patients with a preventable adverse drug event
Endpoint domain: Adverse events/effects
Primary endpoint: number of potential adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in SAO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glomerular Filtration Rate (GFR) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduced candida infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self Reported Relapse Rate at 2 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Self Reported Relapse Rate at 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Time to development of malignancies
Endpoint domain: Mortality/survival
Primary endpoint: UTI Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Serum estrone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in AGE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stage of Exercise Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with a possible diagnosis of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of new evacuation paracentesis after the procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: local infection
Endpoint domain: Adverse events/effects
Primary endpoint: encephalitis
Endpoint domain: Adverse events/effects
Primary endpoint: meningitis
Endpoint domain: Adverse events/effects
Primary endpoint: paralysis or sensory loss
Endpoint domain: Adverse events/effects
Primary endpoint: Local Dynamic Stability (Hip During Straight Walking)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Dynamic Stability (Knee During Straight Walking)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Dynamic Stability (Ankle During Straight Walking)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Dynamic Stability (Hip During Turning With the Prosthesis on the Inside of the Turn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Dynamic Stability (Knee During Turning With the Prosthesis on the Inside of the Turn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenylalanine level in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MOLLI Localization Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progressive Disease (TTPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of Peak-Stimulated Luteinizing Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Posttraumatic Stress Disorder symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of shame
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Bronchopulmonary Dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Re-Hospitalizations and emergency room visits in the short term after discharge from the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Re-Hospitalizations and emergency room visits in the long term after discharge from the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Adaptive Behavior Assessment System Third Edition (ABAS-3)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life - 18 (QoL-18)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CD 2027 plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of the primary somatosensory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Periodontal Inflammation Surface Area (PISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve in one dosing interval (AUC[TAU])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free at two hours following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to lipid-lowering drug implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of bone implant contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-operative Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Narcotic Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intraoperative miosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Respiratory failure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of determined tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Pediatric Anxiety Rating Scale (PARS) Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urine hexose tetrasaccharide (Hex4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale Unpleasantness ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Height Velocity Standard Deviation (SD) Score for Chronological Age From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Post operative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in levels of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in levels of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 'Definite' Diagnosis of TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in length of wetting of Schirmer test strip without anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Surface Disease Index's Environmental Trigger (OSDI-ET) subscale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corneal Fluorescein Staining (Type and Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Visual Acuity with Study Lenses (Snellen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced x-ray radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Accuracy of SUV Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of the apollo™ system
Endpoint domain: Adverse events/effects
Primary endpoint: recurrence rate of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: degree of disability of limbs after ischemic stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Negative toxicology tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Veterans' subjective experience of telemedicine MAT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost of Telemedicine MAT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acute post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of inhaled nebulized AIR001
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom reporting feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of improvement in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of improvement in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of patients with tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Verbal Pain Ratings of Painful Heat and Pressure Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Evoked Potentials (VEP) During Flicker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-operative Plasma IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of risk markers in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Adverse events in terms of changes in Biochemistry
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse events in terms of changes in 12-lead ECGs
Endpoint domain: Adverse events/effects
Primary endpoint: Usability Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: comprehensive assessment battery of higher functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: test of visual memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of MACCE
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with complete hemodynamic data collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve (AUC) of CD25 Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Saturation Rate of CD25 Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Restless Legs Syndrome Quality of Life Instrument (RLSQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Beck Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Phospho-Chk1 Levels in Biopsy Specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in yH2AX Levels in Biopsy Specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotic Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of Dual Sensory Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma MRproANP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Moderate or severe RHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulsatility index in the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction of periorbital wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in end-expiratory lung impedance (EELI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Counseling Center Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of identified genetic variations presumed pathogenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of hypoxia imaging agent HX4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate without complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Mean Hepatitis D Virus (HDV) RNA Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of Teleneurology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade change of ICRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in cross-sectional area of quadriceps muscle group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum trough drug level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed a Successful Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Distance of 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 24-hour mean growth hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin-like growth factor-I concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Body weight and fat mass, specifically abdominal visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: renal function as measured by serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Full-Scale Intelligence Quotient (IQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Acute Graft vs Host Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Severe asthma related events (SARE)
Endpoint domain: Adverse events/effects
Primary endpoint: post-bronchodilator FEV1 % of predicted normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Degree of correction achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of T2D patients with controlled BGL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sars-CoV-2 Seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes